Mark Thursz is professor of hepatology at Imperial College and consultant in hepatology at St Mary's Hospital, London. His clinical interests are in viral hepatitis, alcoholic liver disease and fatty liver disease. He is currently interested in developing programmes for treatment of chronic hepatitis B infection in resource poor settings to reduce the risk of hepatocellular carcinoma.
Professor Thursz' research interests are focussed on the natural history of viral hepatitis and fatty liver disease and the factors which determine chronic infection and progressive liver disease. He has a special interest in the genetic determinants of disease outcomes using genetic association and genome wide scanning to identify causative variants.
Professor Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial.
Professor Thursz is a former secretary of the British Association for Study of the Liver (BASL) and is currently vice-secretary of the European Association for Study of the Liver. In this role he has special responsibility for EU policy and advocacy in Brussels.
et al., In-field evaluation of Xpert® HCV viral load fingerstick assay in people who inject drugs in Tanzania, Liver International, ISSN:1478-3223
et al., Association of troponin level and age with mortality in 250 000 patients: cohort study across five UK acute care centres, Bmj-british Medical Journal, ISSN:1756-1833
et al., Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England, International Journal of Drug Policy, ISSN:0955-3959
et al., 2019, Letter: role of mean platelet volume levels in prediction of major acute cardiovascular events in patients with non-alcoholic fatty liver disease – authors’ reply, Alimentary Pharmacology and Therapeutics, Vol:50, ISSN:0269-2813, Pages:1140-1141
et al., 2019, CD8+ T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction, Ebiomedicine, ISSN:2352-3964